Comparison
Omega-3 (DHA/EPA) vs Rapamycin
Omega-3 (DHA/EPA)
Essential fatty acids critical for brain structure and function. DHA comprises ~40% of brain polyunsaturated fatty acids.
Rapamycin
mTOR inhibitor approved for immunosuppression after organ transplant. Studied off-label for longevity at low intermittent doses.
| Field | Omega-3 (DHA/EPA) | Rapamycin |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–3000mg | 5–10mg |
| Half-life | 24h | — |
| Onset | — | — |
| Evidence | EVIDENCEA | EVIDENCEA |
| Safety | ●●●●● | ●●○○○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 5200 | 36000 |
The comparison in plain English
Auto-generated from dataOmega-3 (DHA/EPA) and Rapamycin are both in the neuroprotective category respectively. Omega-3 (DHA/EPA) Essential fatty acids critical for brain structure and function. Rapamycin mTOR inhibitor approved for immunosuppression after organ transplant.
Bottom line
Omega-3 (DHA/EPA) (evidence A, safety 5/5) matches the evidence base of Rapamycin (evidence A, safety 2/5). Omega-3 (DHA/EPA) has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Omega-3 (DHA/EPA) if
Omega-3 (DHA/EPA) is the better fit when your goal aligns with its mechanism (DHA (docosahexaenoic acid) is a structural component of neuronal cell membranes, maintaining fluidity and supporting receptor function) and the dose range (1000–3000mg) suits your protocol. Half-life is 24h.
Choose Rapamycin if
Rapamycin is the better fit when your goal aligns with its mechanism (Selective inhibitor of mTORC1 (mechanistic target of rapamycin complex 1), reducing protein synthesis and inducing autophagy) and the dose range (5–10mg) suits your protocol. Half-life is —h.